Bayer, Orion begin phase 3 trial of Nubeqa to expand prostate cancer indication

Bayer (OTCPK:BAYZF) and Orion Corp. (OTCPK:ORINY) have started a late-stage trial examining Nubeqa (darolutamide) in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence.
The indication would be for patients who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline.
The trial will examine Nubeqa plus androgen deprivation therapy ("ADT") versus ADT alone.
Nubeqa is already approved for those with non-metastatic castration-resistant prostate cancer, who are at high risk of developing metastatic disease, and metastatic hormone-sensitive prostate cancer.
Read why Seeking Alpha contributor Daniel Schonberger argues that Bayer (OTCPK:BAYRY) is undervalued and a buy.